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ABSTRACT
Metronidazole is used to treat trichomoniasis, bacterial vaginosis, and other diseases. As is the case
with many drugs, physicians often hesitate to use it during pregnancy, particularly in the first
trimester. A review of the nearly four decades’ worth of published literature on metronidazole use
in pregnant women indicates that it is not teratogenic, regardless of the trimester in which it is used.
On the other hand, a number of published, studies indicate that bacterial vaginosis and trichomo-
niasis are associated with preterm birth and low birth weight. Treatment of these conditions with
metronidazole during pregnancy may decrease the incidence of preterm birth and low birth weight,
thus potentially decreasing the complications that can result from prematurity. Infect. Dis. Obstet.
Gynecol. 5:326-335, 1997. (C) 1998 Wiley-Liss, Inc.
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etronidazole, a nitroimidazole that has been
on the U.S. market since 1961, is used to treat
trichomoniasis, bacterial vaginosis (BV), amebiasis,
giardiasis, and numerous anaerobic bacterial infec-
tions. It has been shown to cause cancer in mice
and rats (but not in other species) and to be muta-
genic in some bacterial systems and even embryo-
toxic in some in vitro tests. 1,z The relevance of
these studies to humans is questionable. This pa-
per reviews available human data and some animal
studies that examine the potential for teratogenic-
ity in humans.
HUMAN STUDIES
In a study of women undergoing therapeutic abor-
tion, Heisterberg
3 showed that metronidazole
crossed the placental membrane; placental concen-
trations were approximately 50-65% of those in
maternal plasma. Amon and Amon4 found that, on
occasion, the fetal metronidazole tissue concentra-
tions exceeded those found in maternal plasma. No
controlled clinical trials have been conducted spe-
cifically to determine whether metronidazole is ter-
atogenic in humans. However, numerous reports
have been published in which the effects of met-
ronidazole taken to treat an infection during preg-
nancy were examined. Tables 1-3 give a synopsis
of findings in pregnant women. The larger studies
are briefly summarized below.
Rosa et al.s used a large health management or-
ganization’s database including 104,339 women
who gave birth to normal children and 6,564
women who delivered babies with anomalies.
These included 1,083 women treated with metro-
nidazole in the first trimester. Of these babies,
1,020 were normal and 63 were born with some
anomaly; the relative risk of an anomaly being as-
sociated with metronidazole treatment in this co-
hort was 0.92. These authors reported an increased
risk of spontaneous abortion in patients prescribed
metronidazole in the 120-day period prior to spon-
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TABLE I. Number of congenital anomalies reported in studies in which metronidazole was used
during pregnancy
Trimester treated, n
b
Mothers, n Infants, n Defects, n
Author (control) (control) II III (control)
Stillbirth/abortus/death, n
(control)
Controlled studies
Rosa, et al [5] 1083 1083 1083 63
(104,339) (6564)
Morgan [6] 597 605 62 284 251 12
(9757) (9757) (172)
Heinonen, et al [7] 31 31 31 4
(50282) (50282) (3248)
Piper, et al [8] 1307 1"318 1318 96
(3 ) ( 320) (80)
Hauth, et al [9] 426 426 426 0
(90) (0)
Morales [10] 44 44 44 0
(36) (36) (0)
Robinson, Mirchandi [22] 277 281 14 87 176 6
(277) (277) 7
Uncontrolled studies
Scott-Gray [I I]’ 295 29,5 79 13 103 5
Peterson, et al [12] 206 212 55 78 84 8
Magnin, et al [I 3] 58 58 3 23 32 0
Perl [14] 151 151 4 77 70 3
Pagnozzi, et al [I 5] 61 61 25 0
Sands [I 6] 123 124 I, familial
Watt, Jennison [i 7] 19 19
Zacharias, et al [18] 34 34 0
Williams 9] 14 14 0
Parker, et al [20] 36 36 0
Kotcher, et al [2 I] 34 34 34
Nigam, et al [24] 7 7 0
Beard [25] 23 23 23 5
Scott-Gray [26] 40 40 13 15 12 0
Schram, Kleinman [27] 26 26 0
Lyon, et al [28] 9 9 4 4 0
Andrews, Andrews [29] 19 19 7 0
Cant6, Garcia-Cruz [30] 2 2 2 2 case reports
Pereyra, Lansing [3 I] 42 42 0
Glowinski, Chrusciel [32] II II 2 0 9 0
Gardner, Dukes [33] 18 18 0
Whitelaw, et al [34] 5 5 0
Rodin, Hass [35] 61 61 13 29 19 0
Csonka [36] 7 7 0
Monroe [37] 25 25 10 5 10 0
Ross, van Middelkoop [39] 99 99 0
Carvajal [40] case report
Perl, Ragazzoni [41] 49 49 0
Robinson, Johnston [42] 92 93 3
Doyle, Rolfe [43] 0
135
(not stated)
3
(not stated)
0
(not stated)
4
(8)
0
(0)
0
(0)
(not stated)
10 incl. 2 TAB
13
0
3
0
2
+ TAB
I, Rh factor
0
0
0
3
3
0
0
2
0
2
0
0
4
0
0
0
0
0
0
TAB: therapeutic abortion.
Liveborn.
bTrimester treated, if stated by author. Blanks indicate that trimester treated is not given.
CMultiple courses of therapy.
Blank spaces indicate that the data were not reported.
taneous abortion compared with those prescribed
metronidazole 300-180 days prior to delivery; no
excess risk was found when the population was
compared with women who underwent elective
abortion. The authors state that metronidazole
therapy is frequently avoided during pregnancy;
this may reflect no avoidance of therapy prior to
elective abortions, compared with avoidance of
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TABLE 2. Congenital anomalies reported in published studies of metronidazole treatment in pregnancy
Author Metronidazole* Controls
Morgan [6]
Piper [8]
Controlled studies
7 major, 5 minor (2%)
Accessory digit (I)
Anencephaly + meningomyelocele (I)
Heart valve atresia + situs inversus (11)
Cleft palate + harelip (11)
Myotonia congenital (familial) (11)
Down’s syndrome (111)
Fallot’s tetralogy (111)
Atrial septal defect + accessory digits (111)
Intestinal obstruction (banding) (111)
2-Single unbilical artery (11, III)
96 total defects
16 CNS
6 heart
6 GI
35 musculoskeletal
38 urogenital
2 respiratory
7 hultiple organ systems
Robinson [22] Hypospadias (11)
Skin tag, ear (11)
Hydrocephalus (111)
Club foot (111)
Harelip and cleft palate (111)
Congenital hip (111)
Uncontrolled studies
Peterson [I 2] Cyanotic heart disease (11)
Hydrocephaly (111)
Calcaneus valgus (I, II)
Hypospadius (I, II)
Pyloric stenosis (11)
Hydrocele (I)
Syndactyly (I)
Small testicle (111)
Perl [14] Down’s syndrome (11)
Cardiac defect (11)
Hemangioma
Anencephaly (stillborn)
Beard [25] 2-Hydrocele
Congenital hip dislocation
Unilateral metatarsus varus
Mental retardation (parents also)
Robinson, Johnston [42] Umbilical hernia
Hydrocephalus
Small skin tags on ear
Scott-Gray [I I] Microcephaly + meningocele
Multiple defects
Cardiac lesion
Mild hydrocephaly
Watt, Jennison [I 7] Anencephaly
Sands [I 6] Polydactyly (familial)
Kotcher [21] Crooked foot
Zacharias [18] Rh factor (stillborn)
Cant6 [30] Midline facial defects (I)
96 major, 76 minor (I.8%)
80 total defects
19 CNS
8 heart
5 GI
29 musculoskeletal
25 urogenital
2 respiratory
2 chromosomal
6 multiple organ systems
Harelip
Congenital heart disease
Spina bifida
Blood dyscrasia
Anencephalus
2 club foot
*Roman numeral following defect indicates trimester treated, when reported.
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TABLE 3. Summary of published data reviewing metronidazole treatment in pregnancy
% infants with
Mothers Infants Defects congenital anomalies
Total number treated with metronidazole in controlled studies
3,765 3,788 181
Total number of controls
166,192 166,201
Total number treated with metronidazole, all studies:
Trimester treated, n*
Mothers, n Infants, n III Major & minor defects, n Stillbirth/abortus/death, n
5,333 5,369 2,667 I, 186 805 21 (3.93%) 189 (3.52%)
4.77%
10,071 6.06%
*When known.
therapy in those continuing pregnancy. The man-
ner of presentation of abortion data makes recalcu-
lation impossible. The authors have recognized
that their results are difficult to interpret, since
only computer records of prescription dates, deliv-
ery, and abortion, but no medical details, were
available, and stated that no conclusions can be
drawn.
Morgan6 studied 880 pregnant women: 283 were
untreated, and the remaining 597 received 7-10
days of oral metronidazole therapy, 200 mg, three
times daily. Sixty-two were treated in the first tri-
mester, 284 in the second trimester, and 251 in the
third trimester. The incidence of small-for-dates
births and premature births were not altered. Major
congenital anomalies were found in 1.7% of un-
treated patients and 1.2% of treated patients. In
untreated patients, 2.7% of births had some con-
genital anomaly, compared with 2% in the metro-
nidazole group. The incidence of congenital
anomalies among 9,757 births occurring in the
same hospital during that period was 1.8%.
Heinonen et al. 7 examined malformations in re-
lation to exposure to various drugs in 50,282
mother-child pairs, including 31 exposed to metro-
nidazole. There were four malformed children
born to metronidazole-treated mothers, and a stan-
dardized relative risk estimate of 2.02, which was
not significant. Two of these exposures occurred
during the first trimester, giving a relative risk of
1.39, which was also not significant.
Piper et al.8 compared two cohorts of pregnant
women from the Tennessee Medicaid enrollment
files. The exposed cohort included 1,307 women
who received a metronidazole prescription be-
tween 30 days before and 120 days after their last
normal menstrual period; the controls were 1,311
comparable women who had not received metroni-
dazole. Results were comparable for the two groups
in terms of twin gestations, fetal viability at deliv-
ery, gender ratio, very low birth weight, and major
birth defects. The adjusted risk ratio for all birth
defects among metronidazole-exposed infants
compared with controls was 1.2 (0.9-1.6). The spe-
cific types of defects in exposed and unexposed
groups are similar and are listed for both groups in
Table 2.
A group of 624 women with a history of preterm
birth were enrolled in a metronidazole treatment
trial during their second trimester of pregnancy.
9
The treatment group included 433 women, while
the control group included 191 women who re-
ceived a placebo. The treatment group received
metronidazole, 250 mg, three times daily for seven
days, plus erythromycin, 333 mg, three times daily
for 14 days. The incidence of preterm delivery
(birth at or before 37 weeks’ gestation) was signifi-
cantly decreased only among the 263 women who
had BV when they entered the study: 31% of the
176 treated women with BV delivered preterm,
compared with 49% of the 87 untreated women
with BV (P=0.006). No congenital anomalies were
identified in either the treatment or the placebo
group. (Personal communication to the author from
Dr. Hauth.)
Morales et al.1 enrolled in a clinical trial 80
women with a history of preterm birth who had BV;
congenital anomalies were ruled out at study entry
by ultrasonography. Forty-four patients received
treatment with metronidazole, 250 mg, three times
daily for seven days, and the placebo group re-
ceived identical-appearing vitamin C tablets. More
than one admission to the hospital for preterm la-
bor was experienced by 78% of women in the pla-
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cebo group, compared with 27% of treated patients.
Delivery at <37 weeks occurred in 18% of treated
patients and 39% of patients in the placebo group
(P<0.05). No congenital anomalies were identified
in either group.
Scott_Gray11 monitored 295 pregnant women
who were treated with metronidazole; 79 were
treated during the first trimester, 113 in the second,
and 103 in the third. Five infants were born with
defects (see Tables and 2).
Peterson lz reported on 212 infants born to 206
mothers, ofwhom 55 were treated with metronida-
zole in the first trimester, 78 in the second trimes-
ter, and 84 in the third trimester. There were eight
fetuses aborted or stillborn and eight babies born
with developmental anomalies (3.8%). Two infants
(0.9%) were considered to have major..defects: one
had cyanotic heart disease (mother received met-
ronidazole treatment at 17 weeks of gestation), and
the other, hydrocephaly (mother received metroni-
dazole treatment at 35 weeks of gestation). The
mother of the latter of these two infants had pre-
viously given birth to two infants with hydrocephaly.
Magnin et al. 13 reported no defects in a group of
58 infants born to metronidazole-treated mothers
(three treated in the first trimester, 23 in the sec-
ond, and 32 in the third).
Perl4 reported two serious malformations, two
minor skin abnormalities, and three stillbirths/
deaths among infants born to 151 mothers treated
with metronidazole during pregnancy (four treated
in the first trimester, 77 in the second, 70 in the
third). Infants were monitored for six months after
delivery. One of the two malformed infants had
Down’s syndrome, and the other had a cardiac de-
fect. Both mothers had been treated in the second
trimester.
Pagnozzi et al.s treated 6I women with metro-
nidazole for trichomoniasis during pregnancy.
Three infants were born with low birth weight, but
none were born with major congenital anomalies.
The incidence of low birth weight was stated to be
lower than usually observed.
Sands16 treated 123 women with metronidazole
during pregnancy, the majority during the second
and third trimesters. One infant was stillborn, and
there was one intrapartum death. The only congen-
ital anomaly was a case of familial polydactyly. The
author noted that the incidence of prematurity was
8.1%, considerably lower than the usual 11.7%.
Watt and Jennison
7 monitored 191 women
treated for trichomoniasis with metronidazole; 23
of the women were pregnant. The outcome of four
of the pregnancies was unknown. Sixteen normal
infants were delivered, and one was born with an
encephaly. Two women had abortions, one surgical.
Zacharias8 reported that of 39 pregnant patients
with adequate follow-up who were treated with
metronidazole at various times between two and
8.5 months, 32 mothers delivered infants at term,
and one mother delivered a preterm normal infant
at 7 months of gestation. In addition, one infant
with Rh incompatibility was stillborn (the mother
had had two prior pregnancies that resulted in in-
trauterine deaths caused by erythroblastosis feta-
lis). There were no congenital anomalies.
Williams 19 treated 14 pregnant patients with
metronidazole for trichomoniasis; no patients nor
their fetuses showed any ill effects. Parker et al.z
treated 420 patients, 36 of whom were pregnant,
with metronidazole. An unstated number were
treated in the first trimester. No congenital abnor-
malities were noted. Kotcher et al. el treated 36
pregnant women with metronidazole in the third
trimester. Of the 34 babies for which outcome was
known, one had a congenital defect: a crooked foot.
Robinson and Mirchandiee treated 475 women
with trichomoniasis, 375 of whom were pregnant,
with metronidazole. They reported on 277 women
whose 281 newborns were monitored for at least six
months, and most were tracked for an average of
two years. This same group of mothers had previ-
ously given birth to seven infants with anatomic
anomalies in pregnancies in which they had not
received metronidazole. Fourteen received treat-
ment with metronidazole was during the first tri-
mester, 87 in the second trimester, and 176 in the
third trimester. Six congenital anomalies were re-
ported: none for women treated in the first trimes-
ter, two for women treated in the second trimester,
and four for women treated in the third trimester.
Eight premature births were also reported: one for
a woman treated in the first trimester, four plus a
second twin with toxemia to women treated in the
second trimester, and two plus one stillbirth for
women treated in the third trimester.
Berget and Weber23 reviewed studies that in-
cluded 1,457 infants born to 1,469 metronidazole-
treated mothers, 206 ofwhom received the drug in
the first trimester. Twenty-four children were born
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with malformations, three lethal, six other major,
and 15 minor; there were 12 abortions and 20
deaths. The authors found incidence of malforma-
tions comparable to that of the general population
and concluded that no indications could be found
that metronidazole might be injurious to the fetus
and its development. The studies they reviewed
are included in Tables 1, 2, and 3.
Other studies, summarized in Table 1, have re-
ported results that allowed similar conclusions to
be drawn.24-43
Summarizing these 37 studies (which include
three case reports of defects in offspring of metro-
nidazole-treated mothers3’4), 5,333 mothers were
treated with metronidazole during pregnancy, and
5,369 infants were born to these mothers. Two
hundred eleven major and minor malformations
(3.93%) were recorded. These included some in-
fants with defects which were obviously genetic
(Rh incompatibility, mental retardation in an infant
born to retarded parents, familial polydactyly,
Down’s syndrome). One hundred eighty-nine in-
fants (3.52%) were aborted, stillborn, or died very
early in the postnatal period. Deaths included
three infants from a group of seven pregnant
women treated with metronidazole for amebic,
pyogenic, or mixed hepatic abscess; two of the
mothers died from the abscess as well.z4 If only
studies including controls are considered,s-l,zz
3,765 mothers who gave birth to 3,788 infants were
treated with metronidazole; 181 infants (4.77%)
had congenital defects. This compares favorably
with the 10,071 defects in 166,201 control infants
examined (6.06% congenital anomalies).
Both the spectrum and incidence of defects re-
ported in infants born to metronidazole-treated
mothers approximates that which one would ex-
pect in any large group of infants. In those studies
that included a control group, the incidence or rela-
tive risk of defects with metronidazole treatment
was similar to that found in controls.
Burtin et al.44 have published a metaanalysis in
which the safety of metronidazole in pregnancy
was reviewed, using seven appropriately controlled
studies,s-7,11,1e,3s,4 The odds ratio for teratogene-
sis with vs. without metronidazole was 1.02 (95%
confidence limits, 0.48 2.18). Odds ratio for a
teratogenic effect following exposure during the
first trimester was 0.93 (95% confidence limits, 0.73
1.18). The authors concluded that metronidazole
does not appear to be associated with increased
teratogenic risk.
Searle’s adverse drug experience files (for which
the denominator is unknown) has records of 29 re-
ports of congenital anomalies in which metronida-
zole was taken at some time during pregnancy.
The anomalies reported are as follows: four un-
specified congenital anomalies, two hypospadias,
two ectromelia, two unspecified central nervous
system defects. One infant each was reported with
the following defects: ventricular septal defect;
spina bifida; heart defects/dislocated hip; stillbirth
with malformed kidney; neuromuscular problems
requiring ventilator; megakaryoblastic leukemia,
hepatomegaly, splenomegaly; adrenal neuroblas-
toma; spontaneous abortion; malformed fetus; ce-
rebral problems (apparently hereditary); urogenital
malformation; cleft palate, ectromelia one limb;
cleft palate, optic atrophy; brain damage (cord
around neck; anoxia); brain damage, unspecified;
encephalocele, microcephaly; facial malformation;
hydrocephalus; cerebral dysgenesis, hydrocepha-
lus, microphthalmia, seizures.
A distinct pattern of defects, such as is found
with known chemical teratogens, is missing with
metronidazole in both human and animal studies.
For example, thalidomide caused primarily limb
reduction defects, anotia, and some heart defects.
Very high doses of retinoic acid have been associ-
ated mainly with facial, head, mouth, skeletal and
central nervous system defects.4s The related
drugs isotretinoin and etretinate have been associ-
ated primarily with anomalies of structures that
originate from the cephalic neural crest: cerebellar
malformations; cerebral abnormalities; hydro- and
microcephaly; mental retardation, cranial nerve
deficit; skull abnormalities; ear abnormalities, in-
cluding anotia and deafness; microphthalmia; facial
dysmorphia; and cardiovascular abnormalities.4s’46
Tetracycline causes discolored dentition.4s’47
Streptomycin and kanamycin are associated with
ototoxicity.4z Such specificity is not evident with
metronidazole.
ANIMAL STUDIES
Controlled studies of metronidazole in rats, mice,
and rabbits did not show teratogenic effects.47 Two
well-designed mouse studies44,5 using orally
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 331METRONIDAZOLE IS NOT A HUMAN TERATOGEN STRUTHERS
dosed metronidazole found no teratogenic or feto-
toxic effects; one of these was a multigeneration
study,s
Two papers have reported both fetotoxicity and
teratogenicity in rodents treated with metronida-
zole.sl,s2 Because their results are discordant with
results of other animal or human studies, a more
detailed examination of these papers is warranted.
Metronidazole ("trichomonacide," stated to be
identical to the French product Flagyl) was re-
ported in a Bulgarian study to cause embryotoxic
and teratogenic effects in rats, mice, and guinea
pigs at dose levels corresponding to the human
dose.sl The period that the drug was administered
was apparently the third trimester of pregnancy.
Problems with abortions were experienced in both
treated and untreated groups of guinea pigs but
were more frequent in the metronidazole group.
Birth defects (type unspecified) were reported in
two out of five young in the treated group and
three out of 26 young in the control group. In mice,
"birth defects" were increased and viability some-
what decreased in the metronidazole-treated
group. The rat studies were complicated by canni-
balism of "a majority" of newborns in both treated
and control groups. The paucity of data in the pa-
per and the large number of deaths in both treated
and control groups of all three species used make
these results difficult to interpret,
sl
Giknis and Damjanovse reported fetotoxicity
and teratogenicity in mice treated concomitantly
with metronidazole and high doses of ethanol and
"mild fetotoxicity" with metronidazole alone.
Treatment was given on days 8, 10, 12, and 14. The
route of administration of both metronidazole and
ethanol used was intraperitoneal. Intraperitoneal
dosing of any drug to pregnant mice presents oner-
ous mechanical problems. In the process of four
injections each in 53 pregnant mice, whose wig-
gling uterine horns fill the abdomen, occasional in-
trauterine injection is nearly impossible to avoid.
That is, the actual route of administration of drug
in this study may have been intrauterine in some
cases, rather than intraperitoneal. The median le-
thal does (LDs0) of ethanol has been reported to be
7.8 g/kg.s3 The groups of mice that received etha-
nol were receiving 4 g/kg, more than half of an
LDso dose, and the anesthetic effects of that much
ethanol during the experimental period would
likely have left these mice quite incapacitated for
the better part of the day following dosing, mean-
ing that they may not eat or even drink. Feed con-
sumption and dam weight gain was, unfortunately,
not reported.
In that study,se five congenital defects were re-
ported; one in the metronidazole group, runting, is
misclassified. A fetus of low birth weight would be
considered small for gestational age, but low birth
weight is not a malformation. Chemical teratogens,
in general, produce bilateral defects, or central de-
fects when an organ is not duplicated (e.g., ven-
tricular septal defects) because of their uniform
systemic distribution and consequent effects on
specific developing structures.4s Only two of the
five malformations reported in the metronidazole
group in this study-cleft palate and bilateral cata-
racts- fell into this category.
The statistical calculations were based on indi-
vidual pups rather than litters,sz The dams, not the
pups, were individually dosed, so number of litters
or dams would have been the appropriate number
to use for statistical comparisons. The authors also
neglected to adjust their results for multiple com-
parisons (Bonferroni correction); pairwise test P-
values should be referred to 0.008 to maintain the
experiment-wise error rate of 0.05. Recalculation,
using the appropriate correction and group num-
ber, shows statistical significance only in the etha-
nol/metronidazole group. This would be expected,
due to the gastrointestinal interaction between
ethanol and metronidazole with consequent de-
crease in feed consumption. As feed consumption
in the ethanol-treated groups was likely decreased
anyway, this additional decrease would enhance
chances of malnutrition. Given the problems with
the study, their conclusions appear to be of limited
or questionable significance.
DISCUSSION AND THERAPEUTIC
CONSIDERATIONS
An important consideration for use of metronida-
zole during pregnancy is that it has been shown to
be useful in preventing premature rupture ofmem-
branes (PROM) and preterm birth, major causes of
neonatal morbidity. There are comments in older
literatures4 relating to the association of trichomo-
niasis with puerperal morbidity. Several studies
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have demonstrated that Trichomonas vaginalis infec-
tion is associated with PROM, preterm birth, and
chorioamnionitis. Minkoff et al.ss,s6 found that
women infected with Trichomonas were signifi-
cantly more likely to have PROM; effects of 15
types of microorganisms and of BV were evaluated,
and Trichomonas was the only organism signifi-
cantly associated with PROM. Hardy et al.s7 moni-
tored 115 pregnant teenagers, testing for six differ-
ent pathogens. Cervical Trichomonas infection,
but not infection with other organisms, was signifi-
cantly associated with lower birth weight and ear-
lier delivery than in uninfected mothers or in moth-
ers infected with other organisms; concomitant
Chlamydia infection enhanced the effect of
Trichomonas but did not, by itself, result in pre-
term birth or low birth weight.
Keith et al.s8 has shown that Trichomonas, a mo-
tile organism, can attach to various bacteria. They
suggest that trichomonads may possibly carry
pathogens through the female genital tract into the
uterus and tubes and may be an important factor or
cofactor in causing salpingitis that results in tubal
infertility. If their conclusions are correct, Tricho-
monas may facilitate the ascent into the cervical
canal of Chlamydia, streptococcus group B, Ure-
aplasma, and other bacteria known to be factors in
neonatal infections, premature labor, and chorio-
amnionitis.
Other recent studies have indicated that devel-
opment of BV during pregnancy is linked to an
increased risk of preterm or low-birth-weight in-
fants,s9-61 infection of the chorioamnionic mem-
brane6e or amniotic fluid,
63 and puerperal endome-
tritis.64,6s In a study by Morales et al.1 women who
had previously delivered a preterm infant were
screened for BV between the 13th and 20th week
of gestation. Eighty patients received either met-
ronidazole, 250 mg, three times daily for seven
days, or a placebo during weeks 16-20 of their preg-
nancy. Metronidazole, when compared with placebo,
was associated with fewer hospital admissions for pre-
term labor, fewer episodes of PROM, and fewer in-
fants born with a birth weight below 2,500 g (P<0.05).
There was no significant difference between groups
in the mean gestational age at delivery, although
significantly fewer women in the metronidazole
group delivered before 37 weeks of gestation. All
women were screened for BV again at delivery. In
the metronidazole group, 89% tested negative for
BV, compared with 14% in the placebo group.
Hillier et al.66 reported that in a study of the
association between BV and preterm delivery of
low-birth-weight infants in which more than 10,000
pregnant women were enrolled, women with BV
during the second trimester of pregnancy were 40%
more likely to deliver a premature, low-birth-
weight infant. This relationship remained un-
changed after adjustment for confounding vari-
ables. It was concluded by these investigators that
prevention of even a small proportion of these
births could result in large monetary savings and a
decrease in neonatal morbidity and mortality.
Hauth et al.9 studied 600 pregnant patients at
risk for preterm delivery, randomly assigning them
to receive one of two treatments during the second
trimester: metronidazole, 250 mg, three times daily
for seven days plus erythromycin base, 333 mg,
three times daily for 14 days, or a placebo. These
patients were screened at enrollment for BV,
trichomoniasis, Chlamydia trachomatis, and candidi-
asis. Treatment was found to decrease preterm de-
liveries only in those patients who had BV on initial
examination.
A recent publication of results of a large multi-
centered study (13,816 women) by Cotch et al.67
showed that both BV and trichomoniasis at midges-
tation increased the risk of low birth weight and
preterm delivery. Compared with uninfected
women, women with both infections had a substan-
tially higher incidence of low birth weight (13.4%
vs. 6.6%), preterm delivery (17.3% vs. 10.8%), and
preterm low birth weight (9.2% vs. 4.2%).
According to Hook,68 major congenital anoma-
lies are identified in 2-3% of liveborn infants at
birth; an additional 6-7% are identified in the in-
terval between birth and one year of age. The
causes of birth defects vary; most often the etiology
is unknown. Schardein4s estimates that chemically
induced birth defects probably account for only a
very small fraction-about l%-of the congenital
anomalies seen in the general population. Pru-
dence dictates that exposure during pregnancy be
minimized, and that metronidazole and other drugs
used during pregnancy be given at the lowest ef-
fective dose, taking into account both the benefits
and the possible risk. Data collected to date do not
indicate that metronidazole poses a teratogenic risk
for either animals or humans.
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